Glepaglutide
Long-acting GLP-2 analog being developed by Zealand Pharma for short bowel syndrome.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
An emerging GLP-2 candidate positioned to extend or compete with teduglutide. Once-weekly subcutaneous dosing rather than the daily injections current GLP-2 therapy requires.
- Class
- Long-acting GLP-2 receptor agonist
- Sponsor
- Zealand Pharma
- Stage
- Phase 3
- Lead use case
- Short bowel syndrome with intestinal failure
What it is
Glepaglutide is a synthetic GLP-2 analog engineered for once-weekly or twice-weekly subcutaneous administration in patients with short bowel syndrome (SBS). It builds on the GLP-2 receptor pharmacology established by teduglutide (Gattex), with the key engineering advance being a substantially extended half-life that supports less-frequent dosing.
Current research status
The Phase 3 EASE program in adults with SBS-IF (intestinal failure requiring parenteral support) has read out positive results, supporting Zealand's regulatory submissions. Approval pathways in EU and US are advancing in parallel.
Mechanistic rationale
GLP-2 receptor activation drives intestinal mucosal trophic effects — increased villus height, crypt depth, and absorptive surface area — alongside slowed gastric emptying and reduced intestinal motility. In SBS where surgical resection has reduced absorptive capacity, these trophic effects translate to clinically meaningful reductions in parenteral nutrition requirements. Glepaglutide's half-life extension is achieved through structural modifications including a fatty-acid moiety supporting albumin binding, similar to the engineering used for the GLP-1 class.
Available evidence
EASE Phase 3 (2024 readout) — Glepaglutide reduced parenteral support volume in adults with SBS-IF, supporting the once-weekly and twice-weekly dosing regimens.[1]
Phase 2 program — Established the dose-response and pharmacokinetic profile that supported Phase 3 design.
Why it's interesting
For patients with SBS, the daily injection burden of teduglutide is non-trivial in a population already managing complex parenteral nutrition routines. A once- or twice-weekly alternative could meaningfully improve quality of life and adherence. The molecule also represents the maturation of the GLP-2 therapeutic class, which has been under-developed relative to GLP-1.
Limitations & risks
SBS is a narrow indication, and the GLP-2 class as a whole faces the polyp / neoplasia surveillance considerations that come with chronic intestinal trophic stimulation. Direct head-to-head efficacy data with teduglutide is not the central design of the Phase 3 program. Cost considerations in a rare-disease population will shape access dynamics.
Community discussion notes
Less broadly discussed than incretin candidates given the rare-disease focus, but actively tracked in gastroenterology specialty discourse and SBS patient communities.
The takeaway
Glepaglutide is positioned to become the second approved GLP-2 analog and the first long-acting option in the class. The clinical impact is narrow but meaningful in the SBS population, and the molecule represents a useful case study in how peptide engineering extends previously-daily therapeutics into weekly dosing intervals.
References
- Zealand Pharma. EASE Phase 3 program in short bowel syndrome (corporate disclosure / regulatory filings). https://pubmed.ncbi.nlm.nih.gov/?term=glepaglutide
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583. https://pubmed.ncbi.nlm.nih.gov/24161075/